Alogliptin
Alogliptin
Definition
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines.
Also known as ALOGLIPTIN, Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]- — per NCIT
Also identified as
- ATC A10BH04 per RXNORM
- NCIT NCIT:C76906 per NCIT
- SCTID 702799001 per RXNORM
- SCTID 703669009 per RXNORM
- UNII JHC049LO86 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetes mellitus type 2 | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Pancreas | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.